Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 08, 2016 7:56 AM ET

Biotechnology

Company Overview of Intarcia Therapeutics, Inc.

Company Overview

Intarcia Therapeutics, Inc., a biopharmaceutical company, develops treatments to optimize therapeutic benefits and reduce adverse effects for chronic and life-threatening diseases. The company provides ITCA 650 for the treatment of type 2 diabetes by using its subcutaneous delivery system technology, which is a matchstick-sized device, including a cylindrical titanium alloy reservoir that is inserted under the skin to allow the water from the extracellular fluid to enter the device at one end by diffusing through a semi-permeable membrane directly into a salt osmotic engine that expands to drive a piston at a controlled rate, and forces the drug formulation to be released in a consistent way...

155 Seaport Boulevard

11th Floor

Boston, MA 02210

United States

Founded in 1995

35 Employees

Phone:

617-936-2500

Key Executives for Intarcia Therapeutics, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 47
Chief Financial Officer and Vice President of Finance & Operations
Age: 51
Chief Operating Officer
Chief Scientific Officer and Vice President
Chief Legal Officer, Vice President and General Counsel
Age: 56
Compensation as of Fiscal Year 2015.

Intarcia Therapeutics, Inc. Key Developments

Intarcia Therapeutics, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 09:00 AM

Intarcia Therapeutics, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 09:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Kurt C. Graves, Executive Chairman, Chief Executive Officer and President.

Intarcia Therapeutics, Inc. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 01:50 PM

Intarcia Therapeutics, Inc. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 01:50 PM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Kurt C. Graves, Executive Chairman, Chief Executive Officer and President.

Intarcia Announces New Top-Line Phase 3 Results for Investigational Therapy ITCA 650 In Type 2 Diabetes

Intarcia Therapeutics, Inc. announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment. All patients were on background metformin monotherapy. ITCA 650 is an injection-free GLP-1 receptor agonist in development that continuously delivers exenatide with just once or twice-yearly dosing via a small matchstick-size subdermally placed osmotic mini-pump. In the FREEDOM-2 trial, ITCA 650 met all primary and secondary endpoints, demonstrating superiority over Januvia at every measured time point through and including week 52 endpoints for reduction in HbA1c and reduction in body weight (BW). ITCA 650 is not yet being investigated for the management of obesity. Significantly more patients on ITCA 650 60mcg versus Januvia 100mg achieved the secondary composite endpoint combining glucose reductions of > 0.5% and weight reductions of 2 kg or greater; ITCA 650 results were superior versus Januvia 100mg. Significantly more patients on ITCA 650 60mcg achieved the ADA-recommended HbA1c target of < 7.0% versus Januvia 100mg; ITCA 650 results were superior versus Januvia 100mg. In the FREEDOM-2 trial, ITCA 650 60 mcg/d also demonstrated an overall and G.I. tolerability profile similar to prior Phase 3 results recently presented at ADA in the FREEDOM-1 placebo-controlled trial. Discontinuations for nausea were in the low single digits over the full 12 months of treatment. There were no cases of major hypoglycemia in either study arm and minor events of hypoglycemia were reported in the low single digits for both study arms. The placements and removals of ITCA 650 were very well tolerated and the rate of minor infections at the application site was less than 1% of all procedures in the trial.

Similar Private Companies By Industry

Company Name Region
New Horizons Diagnostic Corp. United States
Bio-Life Labs Inc. United States
DEW Technologies, Inc. United States
Acumen Pharmaceuticals, Inc. United States
BioMarck Pharmaceuticals, Ltd. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 24, 2015
Phoundry Pharmaceuticals, Inc.
Private Placement
April 27, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intarcia Therapeutics, Inc., please visit www.intarcia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.